Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

55.91
Delayed Data
As of May 26
 -2.61 / -4.46%
Today’s Change
46.52
Today|||52-Week Range
91.35
-20.48%
Year-to-Date

Today’s Trading

Previous close58.52
Today’s open57.45
Day’s range55.55 - 58.61
Volume304,845
Average volume (3 months)523,857
Market cap$2.4B
Dividend yield--
Data as of 3:59pm ET, 05/26/2017

Growth & Valuation

Earnings growth (last year)-56.82%
Earnings growth (this year)-13.08%
Earnings growth (next 5 years)+51.01%
Revenue growth (last year)--
P/E ratioNM
Price/Sales20,927.50
Price/Book4.86

Competitors

 Today’s
change
Today’s
% change
CLVSClovis Oncology Inc-2.87-5.21%
AGIOAgios Pharmaceutical...+0.74+1.56%
LGNDLigand Pharmaceutica...-3.31-2.92%
AXONAxovant Sciences Ltd+0.02+0.09%
Data as of 4:00pm ET, 05/26/2017

Financials

Next reporting dateAugust 16, 2017
EPS forecast (this quarter)-$1.72
Annual revenue (last year)$133.0K
Annual profit (last year)-$245.9M
Net profit margin-184,867.67%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Emil D. Kakkis
CFO, Senior VP &
Head-Investor Relations
Shalini Sharp
Corporate headquarters
Novato, California

Forecasts